Wen-Chun Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wen-Chun Chang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Bor-Ching Sheu
Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan
6 shared publications Bor-Ching Sheu
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei City, Taiwan; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei City, Taiwan; Distinguished Professor and Vice President, College of Medicine, National Sun Yat-sen University, Taiwan
5 shared publications- Chi-Hau Chen
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications Kuan-Ju Huang
National Taiwan University Hospital Yunlin Branch, Taiwan
3 shared publicationsSu-Cheng Huang
Department of Obstetrics and Gynecology, Buddhist Tzu-Chi General Hospital, No. 289, Jianguo Road., Xindian Dist., New Taipei City, 231, Taiwan
3 shared publicationsChing Hsu
Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1462-1463
Response to: Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort
- 12 December 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1462-1463
Open AccessResponse to: Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort
- Open Access
- 29 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1416-1422
Pembrolizumab combined with chemotherapy for advanced and recurrent endometrial cancer: A single-center retrospective study
- 29 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1416-1422
Open AccessPembrolizumab combined with chemotherapy for advanced and recurrent endometrial cancer: A single-center retrospective study
- Open Access
- 24 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1852
Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study
Proteinuria is a common adverse event arising from treatment with bevacizumab, requiring diagnostic testing via 24-h urine collection. However, this method is cumbersome. We assessed urine screenings in gynecologic cancer patients from February 2021 to May 2022. Along with a simple urine dipstick (UD), the urine microalbumin, total protein, and creatinine were measured and calculated as the urine albumin to creatinine ratio (UACR) and the urine protein to creatinine ratio (UPCR), which were further adjusted through the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations to be estimated and correlated with 24-h urine total protein content. The incremental cost-effectiveness ratio was used for cost analysis. There were 129 urine samples from 36 patients. The sensitivity and specificity for the UACR were 0.56 and 0.97, and for the UPCR, 0.71 and 0.88, respectively. The 24-h TP correlated strongly with the UACR (r = 0.75; p < 0.001) and UPCR (r = 0.79; p < 0.001) and fair for the simple UD (r = 0.35; p < 0.001). The UPCR saves one unnecessary 24-h urine test for less than a dollar compared to a simple UD. The results indicate that using the UPCR could enhance diagnostic accuracy, lower costs, and reduce unnecessary 24-h urine sampling.
- 24 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1852
Open AccessUrine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study
Proteinuria is a common adverse event arising from treatment with bevacizumab, requiring diagnostic testing via 24-h urine collection. However, this method is cumbersome. We assessed urine screenings in gynecologic cancer patients from February 2021 to May 2022. Along with a simple urine dipstick (UD), the urine microalbumin, total protein, and creatinine were measured and calculated as the urine albumin to creatinine ratio (UACR) and the urine protein to creatinine ratio (UPCR), which were further adjusted through the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations to be estimated and correlated with 24-h urine total protein content. The incremental cost-effectiveness ratio was used for cost analysis. There were 129 urine samples from 36 patients. The sensitivity and specificity for the UACR were 0.56 and 0.97, and for the UPCR, 0.71 and 0.88, respectively. The 24-h TP correlated strongly with the UACR (r = 0.75; p < 0.001) and UPCR (r = 0.79; p < 0.001) and fair for the simple UD (r = 0.35; p < 0.001). The UPCR saves one unnecessary 24-h urine test for less than a dollar compared to a simple UD. The results indicate that using the UPCR could enhance diagnostic accuracy, lower costs, and reduce unnecessary 24-h urine sampling.
- 23 August 2024
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 72, 102686
Symptoms, distress, finances, social support, resource utilization, and unmet care needs of patients with gynecological cancer
- 23 August 2024
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 72, 102686
Symptoms, distress, finances, social support, resource utilization, and unmet care needs of patients with gynecological cancer
- Open Access
- 25 May 2024
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 63 (3) , 414-417
Uterine mesothelial cysts mimicking ovarian cysts in a primipara patient with a history of Cesarean section: A case report and review of the literature
- 25 May 2024
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 63 (3) , 414-417
Open AccessUterine mesothelial cysts mimicking ovarian cysts in a primipara patient with a history of Cesarean section: A case report and review of the literature
- Open Access
- 23 March 2023
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 62 (2) , 286-290
A method of laparoscopic treatment of large adnexal cysts – Two port trocar suction
- 23 March 2023
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 62 (2) , 286-290
Open AccessA method of laparoscopic treatment of large adnexal cysts – Two port trocar suction
- Open Access
- 18 August 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (12) , 2424-2429
Clinical outcome and urodynamic changes of tailored transvaginal mesh surgery for pelvic organ prolapse: A mid-term 40 Months follow-up
- 18 August 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (12) , 2424-2429
Open AccessClinical outcome and urodynamic changes of tailored transvaginal mesh surgery for pelvic organ prolapse: A mid-term 40 Months follow-up
- Open Access
- 11 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4697
Effect of Two-Port Laparoscopic Surgery on Pregnancy Outcomes of Patients with Concurrent Adnexal Masses
Adnexal masses are common in pregnancy, with 2–10% of pregnancies presenting with an ovarian mass and approximately 1–6% of these masses being malignant. For suspected malignancy or masses with symptoms, surgery must be performed as early as possible. We retrospectively investigated the effect of two-port laparoscopic surgery on the outcomes of patients with concurrent adnexal masses between 2012 and 2019 (including large mucinous tumor, large teratoma, serous borderline tumor, and heterotopic pregnancy). Laparoscopic right partial oophorectomy was performed for a 27 cm ovarian mucinous tumor at a gestational age (GA) of 21 weeks, laparoscopic right oophorocystectomy for an 18 cm teratoma at a GA of 10 weeks, and laparoscopic left salpingo-oophorectomy for a 7 cm serous borderline tumor at a GA of 7 weeks after ultrasonographic confirmation of an intrauterine gestational sac with a fetal heartbeat. Laparoscopic excision of a tubal pregnancy was performed in a heterotopic pregnancy at a GA of 12 weeks with massive internal bleeding. Laparoscopic surgery is easier and safe to perform during early pregnancy because a smaller uterus allows for superior visualization. All of these patients had optimal postoperative recovery and normal spontaneous delivery at term. We discussed several aspects of treatment and delivery, namely treatment option (expectant management or surgery), surgery timing (early or advanced pregnancy), surgery type (laparoscopy or laparotomy), and delivery route (normal spontaneous delivery or cesarean section), in patients with concurrent adnexal tumors and their effects on pregnancy outcomes.
- 11 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4697
Open AccessEffect of Two-Port Laparoscopic Surgery on Pregnancy Outcomes of Patients with Concurrent Adnexal Masses
Adnexal masses are common in pregnancy, with 2–10% of pregnancies presenting with an ovarian mass and approximately 1–6% of these masses being malignant. For suspected malignancy or masses with symptoms, surgery must be performed as early as possible. We retrospectively investigated the effect of two-port laparoscopic surgery on the outcomes of patients with concurrent adnexal masses between 2012 and 2019 (including large mucinous tumor, large teratoma, serous borderline tumor, and heterotopic pregnancy). Laparoscopic right partial oophorectomy was performed for a 27 cm ovarian mucinous tumor at a gestational age (GA) of 21 weeks, laparoscopic right oophorocystectomy for an 18 cm teratoma at a GA of 10 weeks, and laparoscopic left salpingo-oophorectomy for a 7 cm serous borderline tumor at a GA of 7 weeks after ultrasonographic confirmation of an intrauterine gestational sac with a fetal heartbeat. Laparoscopic excision of a tubal pregnancy was performed in a heterotopic pregnancy at a GA of 12 weeks with massive internal bleeding. Laparoscopic surgery is easier and safe to perform during early pregnancy because a smaller uterus allows for superior visualization. All of these patients had optimal postoperative recovery and normal spontaneous delivery at term. We discussed several aspects of treatment and delivery, namely treatment option (expectant management or surgery), surgery timing (early or advanced pregnancy), surgery type (laparoscopy or laparotomy), and delivery route (normal spontaneous delivery or cesarean section), in patients with concurrent adnexal tumors and their effects on pregnancy outcomes.
- Open Access
- 12 May 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (11) , 2248-2256
Laparoendoscopic two-site myomectomy (LETS-M) using conventional laparoscopic instruments and the glove-port technique
- 12 May 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (11) , 2248-2256
Open AccessLaparoendoscopic two-site myomectomy (LETS-M) using conventional laparoscopic instruments and the glove-port technique
- Open Access
- 4 January 2021
- Published by Springer Nature in Research Square
Laparoendoscopic Two-Site Myomectomy (LETS-M) Using Conventional Laparoscopic Instruments and The Glove-Port Technique
We aim to evaluate the surgical outcome of laparoendoscopic two-site myomectomy (LETS-M). The medical records of 204 women receiving LETS-M in a tertiary referral center, including 183 surgeries performed by the experienced surgeon and 21 surgeries performed by 3 well-supervised trainees were retrospectively reviewed. The age of the participants was 39.3±6.4 years. The mean diameter of the largest myoma was 8.5±2.2 cm. The mean weight of the myomas was 281.1±183.1 g. The operation time was 97.6±40.2 min, and the intraoperative blood loss was 99.3±115.2 mL. There were 3 (1%) cases of excessive blood loss (more than 500 mL) and 2 (1%) of postoperative hematoma. The only significant difference between the experienced surgeon and trainees was the operation time (92.3±32.2 min vs. 141.2±54 min, p<.001), while the myoma number, myoma diameter, myoma weight, and intraoperative blood loss were not significantly different. The operation time did not differ among different myoma locations. In multivariate analysis, virginity, myoma number, more than 2 large myomas, and myoma size were independent variables for longer operation times. No patient experienced any major complications. The result revealed that LETS-M is a minimally invasive surgical method that is safe, effective, and easy to learn for managing uterine myoma.
- 4 January 2021
- Published by Springer Nature in Research Square
Open AccessLaparoendoscopic Two-Site Myomectomy (LETS-M) Using Conventional Laparoscopic Instruments and The Glove-Port Technique
We aim to evaluate the surgical outcome of laparoendoscopic two-site myomectomy (LETS-M). The medical records of 204 women receiving LETS-M in a tertiary referral center, including 183 surgeries performed by the experienced surgeon and 21 surgeries performed by 3 well-supervised trainees were retrospectively reviewed. The age of the participants was 39.3±6.4 years. The mean diameter of the largest myoma was 8.5±2.2 cm. The mean weight of the myomas was 281.1±183.1 g. The operation time was 97.6±40.2 min, and the intraoperative blood loss was 99.3±115.2 mL. There were 3 (1%) cases of excessive blood loss (more than 500 mL) and 2 (1%) of postoperative hematoma. The only significant difference between the experienced surgeon and trainees was the operation time (92.3±32.2 min vs. 141.2±54 min, p<.001), while the myoma number, myoma diameter, myoma weight, and intraoperative blood loss were not significantly different. The operation time did not differ among different myoma locations. In multivariate analysis, virginity, myoma number, more than 2 large myomas, and myoma size were independent variables for longer operation times. No patient experienced any major complications. The result revealed that LETS-M is a minimally invasive surgical method that is safe, effective, and easy to learn for managing uterine myoma.